These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17660480)

  • 21. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and safety of caspofungin in older infants and toddlers.
    Neely M; Jafri HS; Seibel N; Knapp K; Adamson PC; Bradshaw SK; Strohmaier KM; Sun P; Bi S; Dockendorf MF; Stone JA; Kartsonis NA
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1450-6. PubMed ID: 19114680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.
    Heresi GP; Gerstmann DR; Reed MD; van den Anker JN; Blumer JL; Kovanda L; Keirns JJ; Buell DN; Kearns GL
    Pediatr Infect Dis J; 2006 Dec; 25(12):1110-5. PubMed ID: 17133155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of renal and hepatic impairment on the pharmacokinetics of ospemifene, a tissue-selective estrogen agonist/antagonist.
    Preston RA; Marbury TC; Wajima T; Graham S
    Am J Ther; 2015; 22(3):171-81. PubMed ID: 24413373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
    Allen A; Davis A; Hardes K; Tombs L; Kempsford R
    Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients.
    Saner F; Gensicke J; Rath P; Fruhauf N; Gu Y; Paul A; Radtke A; Malagó M; Broelsch C
    Infection; 2006 Dec; 34(6):328-32. PubMed ID: 17180587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
    Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
    Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
    Hebert MF; Smith HE; Marbury TC; Swan SK; Smith WB; Townsend RW; Buell D; Keirns J; Bekersky I
    J Clin Pharmacol; 2005 Oct; 45(10):1145-52. PubMed ID: 16172179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
    Marbury T; Dowell JA; Seltzer E; Buckwalter M
    J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of caspofungin in ICU patients.
    Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
    J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.
    Hebert MF; Blough DK; Townsend RW; Allison M; Buell D; Keirns J; Bekersky I
    J Clin Pharmacol; 2005 Sep; 45(9):1018-24. PubMed ID: 16100295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation.
    Sirohi B; Powles RL; Chopra R; Russell N; Byrne JL; Prentice HG; Potter M; Koblinger S
    Bone Marrow Transplant; 2006 Jul; 38(1):47-51. PubMed ID: 16715107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey.
    Groll AH; Attarbaschi A; Schuster FR; Herzog N; Grigull L; Dworzak MN; Beutel K; Laws HJ; Lehrnbecher T
    J Antimicrob Chemother; 2006 Mar; 57(3):527-35. PubMed ID: 16431856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar).
    Carr RA; André AK; Chen P; Grabowski BA; Chang MS; Locke CS; Williams LA; Chojkier M
    Nephron Clin Pract; 2006; 103(3):c100-5. PubMed ID: 16534233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
    Louie A; Deziel M; Liu W; Drusano MF; Gumbo T; Drusano GL
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5058-68. PubMed ID: 16304173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
    Breit SM; Hariprasad SM; Mieler WF; Shah GK; Mills MD; Grand MG
    Am J Ophthalmol; 2005 Jan; 139(1):135-40. PubMed ID: 15652837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
    Lauring B; Li XS; Liu Y; Corr C; Lazarus N; Cote J; Larson P; Levonas AO; Lasseter KC; Preston RA; Smith WB; Lai E; Wagner JA
    J Clin Pharmacol; 2014 Nov; 54(11):1247-55. PubMed ID: 24782116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.
    Pettengell K; Mynhardt J; Kluyts T; Lau W; Facklam D; Buell D;
    Aliment Pharmacol Ther; 2004 Aug; 20(4):475-81. PubMed ID: 15298643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
    Wiederhold NP; Kontoyiannis DP; Chi J; Prince RA; Tam VH; Lewis RE
    J Infect Dis; 2004 Oct; 190(8):1464-71. PubMed ID: 15378439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.